查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1610204

癌細胞病毒治療市場：按病毒類型、應用和最終用途 - 2025-2030 年全球預測

Oncolytic Virus Therapies Market by Virus Type (Genetically Engineered Oncolytic Viruses, Oncolytic Wild-type Viruses), Application (Breast Cancer, Lung Cancer, Melanoma), End Use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年癌細胞病毒治療市值為1.1753億美元，預計2024年將達到1.325億美元，複合年成長率為15.45%，到2030年將達到3.213億美元。

癌細胞病毒療法是癌症治療的一個有前景的前沿領域，涉及使用基因工程或天然存在的病毒來選擇性地感染和破壞癌細胞，同時不傷害正常組織。癌症盛行率的上升和傳統治療方法的局限性凸顯了對此類創新方法的需求。這些治療方法已應用於治療多種癌症，包括黑色素瘤、神經膠母細胞瘤和胰腺癌，並且主要用於醫療機構和實驗室。該市場受到幾個關鍵成長要素的影響，例如基因工程的進步、癌症研究投資的增加以及對標靶治療的需求不斷成長。該市場的一個重要機會在於開拓聯合治療，利用溶瘤病毒與免疫療法和化療的協同效應來提高療效並擴大治療範圍。

主要市場統計
基準年[2023] 11753萬美元
預計年份 [2024] 1.325 億美元
預測年份 [2030] 3.213 億美元
複合年成長率（%） 15.45%

影響成長的主要限制包括嚴格的臨床試驗要求和潛在的安全問題導致的監管障礙，以及病毒遞送和標靶化腫瘤的挑戰。此外，高昂的研發成本和強大參與者的競爭格局也帶來了重大挑戰。然而，增強病毒選擇性和效力、開發新的遞送方法以及探索新病毒株等創新領域為業務成長提供了重大機會。市場的性質目前正處於起步階段，但正在迅速發展階段，公共和私營部門都進行了大量投資。該研究向相關人員提出的建議包括促進與學術和生物技術機構的合作，以推進研究並保持競爭優勢；擴大全球合作夥伴關係以加強市場滲透；以及重點關注針對患者群體的個性化醫療方法，以最大限度地提高臨床和市場成功。

市場動態：快速發展的癌細胞病毒治療市場揭示的關鍵市場洞察

供需的動態交互作用正在改變癌細胞病毒治療市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 世界人口癌症發生率上升
    • 傳播免疫療法的意識計劃
  • 市場限制因素
    • 與癌細胞病毒療法相關的風險和併發症
  • 市場機會
    • 持續研發開發先進的癌細胞病毒療法
    • 癌細胞病毒療法作為精準醫學策略的興起
  • 市場挑戰
    • 圍繞 Oncolyte 病毒治療的複雜法律規範

波特五力：開拓癌細胞病毒治療市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解癌細胞病毒治療市場的外部影響

外部宏觀環境因素在塑造癌細胞病毒治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解癌細胞病毒治療市場的競爭格局

對癌細胞病毒治療市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣癌細胞病毒治療市場供應商績效評估

FPNV 定位矩陣是評估癌細胞病毒治療市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了癌細胞病毒治療市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對癌細胞病毒治療市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界人口癌症發生率上升
      • 促進免疫療法的意識計劃
    • 抑制因素
      • 與癌細胞病毒療法相關的風險和併發症
    • 機會
      • 持續研發開發先進的癌細胞病毒療法
      • 癌細胞病毒療法作為精準醫學策略的興起
    • 任務
      • 圍繞溶瘤病毒治療的複雜法規結構
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章按病毒類型分類的癌細胞病毒治療市場

  • 基因工程溶瘤病毒
  • 溶瘤野生型病毒

第7章癌細胞病毒治療市場：依應用分類

  • 乳癌
  • 肺癌
  • 惡性黑色素瘤
  • 卵巢癌
  • 攝護腺癌

第8章癌細胞病毒治療市場：依最終用途

  • 癌症研究組織
  • 醫院
  • 專科診所

第9章美洲癌細胞病毒治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第10章亞太癌細胞病毒治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第11章 歐洲、中東和非洲的癌細胞病毒治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第12章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Amunbio Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • BioInvent International AB
  • Boehringer Ingelheim International GmbH
  • Calidi Biotherapeutics, Inc.
  • Candel Therapeutics
  • Daiichi Sankyo Company Ltd.
  • Elicera Therapeutics AB
  • EpicentRx, Inc.
  • Genelux Corporation
  • Hookipa Pharma Inc.
  • Imvaq Therapeutics
  • Istari Oncology, Inc.
  • Johnson & Johnson Services, Inc.
  • Lokon Pharma AB
  • Merck & Co., Inc.
  • Orgenesis Inc.
  • Pfizer, Inc.
  • Protheragen Inc.
  • Seneca Therapeutics, Inc.
  • Takara Bio Inc.
  • TILT Biotherapeutics
  • Treovir LLC
  • Wuhan Binhui Biotechnology Co Ltd
Product Code: MRR-007C484E5E64

The Oncolytic Virus Therapies Market was valued at USD 117.53 million in 2023, expected to reach USD 132.50 million in 2024, and is projected to grow at a CAGR of 15.45%, to USD 321.30 million by 2030.

Oncolytic virus therapies represent a promising frontier in cancer treatment, focusing on the use of genetically engineered or naturally occurring viruses to selectively infect and destroy cancer cells while sparing normal tissues. The rising prevalence of cancer, coupled with the limitations of traditional therapies, underscores the necessity for such innovative approaches. These therapies are applied in the treatment of a variety of cancers, including melanoma, glioblastoma, and pancreatic cancer, among others, and are primarily used by healthcare institutions and research laboratories. The market is influenced by several key growth factors, including advances in genetic engineering, increasing investment in cancer research, and the growing demand for targeted therapies. A major opportunity within this market lies in the development of combination therapies, which leverage the synergistic effects of oncolytic viruses with immunotherapies or chemotherapies, thereby enhancing efficacy and broadening therapeutic scope.

KEY MARKET STATISTICS
Base Year [2023] USD 117.53 million
Estimated Year [2024] USD 132.50 million
Forecast Year [2030] USD 321.30 million
CAGR (%) 15.45%

The major limitations impacting growth include regulatory hurdles due to stringent clinical trial requirements and potential safety concerns, as well as challenges related to the delivery and targeting of viruses to tumors. Additionally, high R&D costs and a competitive landscape with strong players pose significant challenges. Nonetheless, areas of innovation like the enhancement of virus selectivity and potency, the development of new delivery methods, and exploration of novel virus strains present vast opportunities for business growth. As for market nature, it is currently in a nascent but rapidly evolving stage with significant investments from both public and private sectors. Recommendations for stakeholders include fostering collaborations with academic and biotech institutions to drive research and maintain competitive advantage, expanding partnerships globally to enhance market penetration, and focusing on personalized medicine approaches to cater to specific patient subsets, thus maximizing clinical and market success.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Oncolytic Virus Therapies Market

The Oncolytic Virus Therapies Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidence of cancer among the global population
    • Awareness program to promote immunotherapy
  • Market Restraints
    • Risk and complication associated with oncolytic virus therapies
  • Market Opportunities
    • Ongoing R&D to develop advanced oncolytic virus therapies
    • Rise of oncolytic virus therapies as a precision medicine strategy
  • Market Challenges
    • Complex regulatory framework surrounding oncolytic virus therapy

Porter's Five Forces: A Strategic Tool for Navigating the Oncolytic Virus Therapies Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Oncolytic Virus Therapies Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Oncolytic Virus Therapies Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Oncolytic Virus Therapies Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Oncolytic Virus Therapies Market

A detailed market share analysis in the Oncolytic Virus Therapies Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Oncolytic Virus Therapies Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Oncolytic Virus Therapies Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Oncolytic Virus Therapies Market

A strategic analysis of the Oncolytic Virus Therapies Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Oncolytic Virus Therapies Market, highlighting leading vendors and their innovative profiles. These include Amunbio Inc., Astellas Pharma Inc., AstraZeneca PLC, BioInvent International AB, Boehringer Ingelheim International GmbH, Calidi Biotherapeutics, Inc., Candel Therapeutics, Daiichi Sankyo Company Ltd., Elicera Therapeutics AB, EpicentRx, Inc., Genelux Corporation, Hookipa Pharma Inc., Imvaq Therapeutics, Istari Oncology, Inc., Johnson & Johnson Services, Inc., Lokon Pharma AB, Merck & Co., Inc., Orgenesis Inc., Pfizer, Inc., Protheragen Inc., Seneca Therapeutics, Inc., Takara Bio Inc., TILT Biotherapeutics, Treovir LLC, and Wuhan Binhui Biotechnology Co Ltd.

Market Segmentation & Coverage

This research report categorizes the Oncolytic Virus Therapies Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Virus Type, market is studied across Genetically Engineered Oncolytic Viruses and Oncolytic Wild-type Viruses.
  • Based on Application, market is studied across Breast Cancer, Lung Cancer, Melanoma, Ovarian Cancer, and Prostate Cancer.
  • Based on End Use, market is studied across Cancer Research Institutes, Hospitals, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidence of cancer among the global population
      • 5.1.1.2. Awareness program to promote immunotherapy
    • 5.1.2. Restraints
      • 5.1.2.1. Risk and complication associated with oncolytic virus therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing R&D to develop advanced oncolytic virus therapies
      • 5.1.3.2. Rise of oncolytic virus therapies as a precision medicine strategy
    • 5.1.4. Challenges
      • 5.1.4.1. Complex regulatory framework surrounding oncolytic virus therapy
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Oncolytic Virus Therapies Market, by Virus Type

  • 6.1. Introduction
  • 6.2. Genetically Engineered Oncolytic Viruses
  • 6.3. Oncolytic Wild-type Viruses

7. Oncolytic Virus Therapies Market, by Application

  • 7.1. Introduction
  • 7.2. Breast Cancer
  • 7.3. Lung Cancer
  • 7.4. Melanoma
  • 7.5. Ovarian Cancer
  • 7.6. Prostate Cancer

8. Oncolytic Virus Therapies Market, by End Use

  • 8.1. Introduction
  • 8.2. Cancer Research Institutes
  • 8.3. Hospitals
  • 8.4. Specialty Clinics

9. Americas Oncolytic Virus Therapies Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Oncolytic Virus Therapies Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Oncolytic Virus Therapies Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Amunbio Inc.
  • 2. Astellas Pharma Inc.
  • 3. AstraZeneca PLC
  • 4. BioInvent International AB
  • 5. Boehringer Ingelheim International GmbH
  • 6. Calidi Biotherapeutics, Inc.
  • 7. Candel Therapeutics
  • 8. Daiichi Sankyo Company Ltd.
  • 9. Elicera Therapeutics AB
  • 10. EpicentRx, Inc.
  • 11. Genelux Corporation
  • 12. Hookipa Pharma Inc.
  • 13. Imvaq Therapeutics
  • 14. Istari Oncology, Inc.
  • 15. Johnson & Johnson Services, Inc.
  • 16. Lokon Pharma AB
  • 17. Merck & Co., Inc.
  • 18. Orgenesis Inc.
  • 19. Pfizer, Inc.
  • 20. Protheragen Inc.
  • 21. Seneca Therapeutics, Inc.
  • 22. Takara Bio Inc.
  • 23. TILT Biotherapeutics
  • 24. Treovir LLC
  • 25. Wuhan Binhui Biotechnology Co Ltd

LIST OF FIGURES

  • FIGURE 1. ONCOLYTIC VIRUS THERAPIES MARKET RESEARCH PROCESS
  • FIGURE 2. ONCOLYTIC VIRUS THERAPIES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ONCOLYTIC VIRUS THERAPIES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ONCOLYTIC VIRUS THERAPIES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ONCOLYTIC VIRUS THERAPIES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ONCOLYTIC VIRUS THERAPIES MARKET DYNAMICS
  • TABLE 7. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY ENGINEERED ONCOLYTIC VIRUSES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ONCOLYTIC WILD-TYPE VIRUSES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 147. ONCOLYTIC VIRUS THERAPIES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 148. ONCOLYTIC VIRUS THERAPIES MARKET, FPNV POSITIONING MATRIX, 2023